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Abstract Several exogenous or endogenous factors can lead
to inflammatory heart disease. Beside infectious myocarditis,
other systemic inflammatory disorders such as sarcoidosis,
systemic lupus erythematosus (SLE), systemic sclerosis
(SSc), Churg-Strauss syndrome, and rheumatoid arthritis can
affect the myocardium. Myocardial inflammation may have a
major impact on the outcome of these patients, resulting in
sudden cardiac death, severe arrhythmias, or end-stage heart
failure. The current gold standard for definite confirmation of
inflammatory heart disease is endomyocardial biopsy (EMB),
but is invasive and suffers low sensitivity and specificity due
to sampling errors. Thus, non-invasive methods for detecting
the extent and changes over time of the inflammatory myo-
cardial disease are needed. Cardiac magnetic resonance
(CMR) is such a non-invasive method. We will describe and
discuss different approaches for CMR assessment of inflam-
matory myocardial disease including early gadolinium en-
hancement (EGE), T2-weighted imaging, late gadolinium en-
hancement (LGE), the newer mapping proton relaxation
techniques (T1 pre-contrast, T1 post-contrast, T2 mapping),
and the hybrid PET/MRI technique.
Keywords Myocardial inflammation . Cardiovascular
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Introduction
Several exogenous or endogenous factors can lead to acute or
chronic inflammatory heart disease. Beside infectious myo-
carditis, which is mostly viral in origin, other systemic inflam-
matory disorders such as sarcoidosis, systemic lupus erythe-
matosus (SLE), systemic sclerosis (SSc), Churg-Strauss syn-
drome, and rheumatoid arthritis can affect the myocardium.
Myocardial inflammation may have major impact on the
outcome of these patients, resulting in sudden cardiac death,
severe arrhythmias, or end-stage heart failure [1••]. Currently,
a definite diagnosis of inflammatory heart disease requires
endomyocardial biopsy (EMB) [2], which is the only proce-
dure that can directly assess the extent of myocardial inflam-
mation and clarify the underlying pathophysiology and its
triggers, potentially yielding to adequate treatment of these
patients. However, it is invasive and suffers from several lim-
itations including low sensitivity and specificity due to sam-
pling errors. Thus, new non-invasive methods for detecting
and following inflammatory myocardial disease are needed
in addition to biopsy.
Cardiac magnetic resonance (CMR) is such a new non-
invasive method, which has high spatial resolution, allows
evaluation of morphology, function, and tissue characteriza-
tion as a one stop shop, and works without any radiation. In
this manuscript, we will describe and discuss different
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approaches for CMR assessment of inflammatory myocardial
disease (see Table 1) including early gadolinium enhancement
(EGE), T2-weighted imaging, late gadolinium enhancement
(LGE), the newer mapping proton relaxation techniques (T1
pre-contrast, T1 post-contrast, T2 mapping), and the hybrid
novel PET/MRI technique.
CMR Techniques
Early Gadolinium Enhancement (EGE)
Acute inflammation leads to hyperemia, and some reports
describe an increased early uptake of gadolinium in these
areas [3]. Thus, after contrast application, signal intensity is
elevated in the first few minutes compared to skeletal muscle,
which can be quantified on spin echo images. However, the
exact mechanism of EGE is less clear and non-specific, and
image quality can be significantly affected by motion artifacts
due to irregular heart rhythms and breathing patterns. Hence,
EGE alone is usually insufficient for the diagnosis of
myocardial inflammation. It is most informative when posi-
tive on good-quality images in combination with other tissue
characterization techniques, and while it can be used clinical-
ly, many centers tend to reserve EGE as a research tool.
T2-Weighted Images
T2 is the time of transverse magnetization decay, which is
prolonged in edematous, inflammatory myocardial tissue,
appearing bright on T2-weighted images. Similar to EGE
and using T2 dark-blood sequences, myocardial signal is
indexed to skeletal muscle signal intensity. The underlying
assumption to this approach is, that skeletal muscle is not
influenced by inflammation, which seems quite problematic
in acute viral or systemic inflammatory diseases.
On dark-blood T2-weighted imaging, the diagnosis of
global myocardial edema is made when the ratio is >1.9 [4].
Unfortunately, image quality of this method depends heavily
on a regular, normofrequent rhythm, and patient ability to
breath-hold during the image acquisition. Furthermore, this
method is prone to bright signal artifacts adjacent to the
subendocardium due to poor dark-blood preparation of
slow-flow blood within the LV cavity. Newer bright-blood
T2-weighted sequences overcome some of these limitations,
but were not shown to be superior to dark-blood T2-weighted
imaging in the evaluation of global myocardial edema and
myocarditis [5•, 6••].
Late Gadolinium Enhancement
LGE images are acquired late (15–25 min) after application of
gadolinium. At that time, contrast is washed out in normal
myocardium (which is nulled), but in regions with enlarged
extracellular/interstitial space due to acute necrosis, chronic
scar, or fibrotic tissue, the contrast agent exhibit delayed wash-
out, appearing hyperintense on the images [7]. Hence, in com-
parison to EGE and T2-weighted imaging, LGE typically re-
veals areas of irreversible damage, such as acute necrosis and
chronic fibrosis. It has its strengths in detecting focal process-
es, whereas in diffuse processes this technique has its limita-
tions. Nevertheless, LGE is the most frequently used and best
established method for myocardial tissue characterization,
useful not only in diagnosing non-ischemic cardiac diseases,
but also in prognostication [1••, 8•, 9•]. Furthermore, in com-
parison to EGE and T2-weighted imaging, LGE is best vali-
dated against histological evidence of myocarditis [10, 11].
“Two Out of Three Is Better than One?”
There is an ongoing debate about the best diagnostic approach
to inflammatory heart disease using different CMR sequences.
In 2009, some experts formulated an approach to detect myo-
cardial inflammation using EGE, T2-weighted, and LGE
Table 1 How to approach myocardial inflammation by CMR
CMR technique Pros Cons
Early gadolinium
enhancement
(EGE)
Hyperemia Image quality/artifacts
Scarce validation
against histology
Mechanism unclear
T2-weighted images Edema, free water Image quality/artifacts
Scarce validation
against histology
No prognostic data
Late gadolinium
enhancement
(LGE)
Scar/necrosis
Best validation against
histology
Widely available/usually
good quality
Prognostic impact
Indicating irreversible
damage but not
specific for
inflammation
Only focal processes
Correct inversion time
important
T1 mapping native Diffuse fibrosis
Edema, free water
No contrast agent
Short acquisition protocol
Not clinical routine
Variety of sequences
Different normal
ranges
High T1 not specific
Extracellular
volume (ECV)
quantification
Expansion of extracellular
space: edema, fibrosis,
amyloid deposition
Not clinical routine
Motion artifacts
T2 mapping Edema, free water
No contrast agent
Short acquisition protocol
Not clinical routine
Interindividual
variability
PET/MR Combining detection of
inflammation (PET)
with high-resolution
tissue characterizing
(MR)
Expensive
Not widely available
Radiation exposure
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imaging. Based on collective evidence available at that time,
albeit small number studies, the diagnostic accuracy of acute
myocarditis may be improved when two out of the three im-
aging techniques were positive, also known as the “Lake
Louise criteria” [12]. This is sensible in principle, as increas-
ing the number of measurements may increase the diagnostic
yield for detecting disease, although EGE and T2-weighted
techniques often require longer acquisition times and image
quality prone to motion artifacts, making these challenging to
apply especially in acutely ill patients who have tachyarrhyth-
mia and difficulty breath-holding.
T1 Mapping Pre-/post-contrast
Recently developed pre-contrast T1 quantitative mapping
techniques represent a fundamental step forward in the non-
invasive assessment of myocardial inflammation [13]. Despite
saturation recovery and inversion recovery based T1 mapping
techniques being developed since the 1980s [14, 15], impor-
tant challenges impeded their clinical application [16]. It is
only since a more robust and reproducible mapping sequence
(e.g., the modified Look-Locker inversion recovery (MOLLI)
sequence) [17] has become available that wider clinical appli-
cations have become possible. Technical advances allowing
for shorter acquisitions and shorter breath-holds (such as the
ShMOLLI technique) facilitate the implementation in acutely
ill patients [18, 19•, 20].
Post-contrast T1 mapping techniques are also available;
these are currently being used to assess for expansion of in-
terstitial space/fibrosis (extracellular volume, ECV) and dis-
tinguish it from replacement fibrosis (such as scarred myocar-
dium) [21, 22]. Using an extravascular gadolinium contrast
medium, once an equilibrium distribution between blood
and tissue is attained, the partition coefficient of the contrast
can be derived using pre- and post-contrast T1 values of the
blood and myocardium. Further methods such as equilibrium
contrast CMR (EQ-CMR) [23] and dynamic equilibrium
CMR [24] adjust for the hematocrit to derive the ECV.
The diagnostic accuracy of T1 mapping techniques can be
hampered by motion artifacts due to inconsistent breath-
holding or patient movements. To overcome these limitations,
technical developments allowing for motion correction and
co-registration are now available [25].
T2 Mapping
Spin echo-based T2 mapping techniques are known to be
prone to effects of cardiac motion and stimulated echoes
[26]. T2 mapping techniques using T2-prepared steady-state
free precession (T2p-SSFP) were initially developed for
BOLD imaging [27]. Using a similar mapping scheme, Giri
et al. [28], validated the technique and demonstrated its in-
creased accuracy in detecting T2 variations across the
myocardium compared not only to standard T2-weighted
techniques but also to spin echo-based T2 mapping tech-
niques. Further developments aiming specifically to address
misregistration of the parametric maps are available using
navigator gating and map registration, enabling a more
robust-free breathing T2 mapping technique [29].
T1/T2 Mapping in Myocardial Inflammation/Edema
Myocardial inflammation and edema are characterized by an
increase in free water content, which prolongs both T2 and T1
relaxation times. Myocardial T1 and T2 mapping have been
validated against microspheres to detect myocardial edema in
experimental animal models [30••] and also in human clinical
populations with superior diagnostic performance to conven-
tional T2-weighted techniques [5•, 31]. Quantitative T1 and
T2 mapping techniques are well suited to detect myocardial
inflammation and edema, which are common final pathways
of myocardial injury in a number of myocardial conditions,
with potentially high sensitivity and ability to locate small
areas of abnormality.
PET/MRI
PET/MRI combines the strengths of both techniques. PET is a
non-invasive imaging technique, which can detect metabolic
active processes with high sensitivity: 18F-FDG PET cumu-
lates in inflammatory regions due to the glycolytic activity of
cells, which participate in inflammatory processes (neutro-
phils, monocytes/macrophages). Disadvantages of PET are
radiation exposure and reduced spatial resolution, so small
areas of inflammation might be missed. Hence, a combination
with MRI (providing high spatial resolution and lack of radi-
ation exposure) seems reasonable [32].
Clinics
Myocarditis
Viral myocarditis is the most common inflammatory heart
disorder. Symptoms and clinical presentation may vary, mak-
ing the diagnosis a challenge. Furthermore, the clinical course
comprises a wide spectrum ranging from complete recovery to
terminal heart disease or sudden cardiac death. Autopsy stud-
ies revealed that myocarditis is responsible for 5 to 20 % of
sudden deaths in young adults [33], so getting the diagnosis
right is of vital importance in this population.
CMR and its unique ability of non-invasive tissue charac-
terization are extremely helpful in the work-up of suspected
myocarditis. There are three stages of myocardial alterations
in these patients: firstly, myocardial damage due to the trigger;
secondly, myocardial inflammation by the host immune
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system; and thirdly, chronic myocardial inflammation, which
may result in myocardial fibrosis, leading to remodeling,
consequent ventricular dysfunction [34] and arrhythmic
substrates.
These alterations lead to acute myocardial necrosis and/or
chronic scarring/fibrosis reflected by subepicardial or intra-
mural regions of LGE, often patchy, and preferentially located
in the posterolateral wall [10], see Fig. 1.
In the setting of viral myocarditis, CMR studies with LGE
are being performed for more than 10 years, first looking at the
diagnostic performance of the technique, followed by prog-
nostic data. To date, there is clear evidence that positive LGE
is associated with an adverse outcome: patients with LGE are
at increased risk of suffering adverse cardiac events. Grün
et al. demonstrated in more than 220 patients with biopsy-
proven viral myocarditis that the presence of LGE is the best
independent predictor of all-cause mortality and of cardiac
mortality [1••]. Furthermore, patients with no LGE have an
excellent prognosis. This was confirmed by Schumm and
Greulich et al. in a large study with more than 400 patients
with suspected myocarditis (“all comers”): patients who had a
CMR scan without pathological findings (normal left ventric-
ular ejection fraction, normal left ventricular enddiastolic vol-
ume, no LGE) had a good prognosis, independent of their
clinical symptoms and other findings [9•]. Nevertheless, we
have to keep in mind that not all LGE-positive patients will
suffer an event, but they are at an increased risk to do so.
Despite the limitations of EGE and T2-weighted imag-
ing, these techniques may be useful in supporting the
acute nature of the inflammatory process when images
are diagnostic. Friedrich et al. recently published data on
35 patients with suspected acute myocarditis, in whom the
overall diagnostic accuracy of “T2 and/or LGE” was sig-
nificantly better than LGE alone. For patients in whom a
high positive likelihood ratio is needed, the full Lake
Louise criteria may be useful [35]. However, as described
above, these techniques can be challenging to apply in the
practical clinical setting, and novel quantitative mapping
techniques may circumvent many of the recognized tech-
nical and methodological limitations.
 
Cine LGE T2 
 4 CV
SAX 
Fig. 1 CMR of a 28-year-old male presenting with dyspnea and chest
pain 5 days after flu-like symptoms. Due to ST elevation and elevated
cardiac enzymes, the patient underwent coronary angiography where
coronary stenosis could be excluded. Cine images reveal global
preserved left ventricular ejection fraction (LVEF=60 %) with discrete
hypokinesia at the lateral wall. LGE is present in multiple locations (white
arrows), suggestive of myocarditis. The acute nature of the disease is
demonstrated by positive dark-blood T2W images displaying a clear
bright signal in the lateral wall, in an area consistent with LGE findings.
Note that on the correspondent T2-weighted images in the long-axis,
these lesions are not well delineated. This patient received state of the
art heart failure medication (betablocker, ARB); in the next few months,
the initial extensive LGE lesions decreased in size (which could be
observed at a subsequent CMR scan) and the patients complaints
resolved completely
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T1 Mapping and ECV
Recently, mapping techniques have been shown to have great
utility in this disease owing to its sensitivity to detecting myo-
cardial water and pixel-wise quantification. Ferreira and
Piechnik et al. [6••] first demonstrated that native T1 mapping
using the ShMOLLI technique [18, 36••] is a superior diag-
nostic technique (ROC area-under-the-curve 0.95) compared
to conventional T2-weighted imaging, with an equivalent per-
formance to LGE. Not only can native T1 mapping be used as
a novel diagnostic criterion like the Lake Louise criteria, with
superior sensitivity to T2-weighted and LGE imaging, but
native T1 maps can also display the typical non-ischemic pat-
terns in acute myocarditis without the need for gadolinium
contrast agents [37]. In addition, T1 mapping offers a signif-
icant incremental diagnostic value, detecting additional
areas of myocardial involvement beyond T2-weighted
and LGE imaging and identified extra (30 %) cases
when at least one of these conventional methods failed
to identify abnormalities [37].
Compared to the diagnostic performance of some of the
Lake Louise criteria, native T1 mapping, as a method for
imaging edema, may replace dark-blood T2-weighted imag-
ing either as a single criterion or in combination with LGE.
ShMOLLI T1 mapping offers a number of advantages to con-
ventional dark-blood T2-weighted imaging such as for cases
in which tachyarrhythmia, patient inability to perform long
breath-hold or skeletal muscle inflammation lead to non-
diagnostic or false-negative images. The added ability of T1
mapping to demonstrate non-ischemic patterns of myocardial
injury using incremental thresholds means that T1 mapping
can effectively act as a method for both edema and LGE pat-
tern imaging. In the future, it may be possible to perform a
gadolinium-free CMR protocol using cine and T1 mapping,
with T1 mapping as a single criterion demonstrating around
90 % in sensitivity, specificity, accuracy, PPV, and NPV [37].
Luetkens et al. [38] compared the diagnostic performance
of the Lake Louise criteria, native T1 relaxation times and
ECVat 3 Tesla and found that native T1 mapping significantly
outperformed the other techniques tested (ROC area under the
curve 0.94), with a high diagnostic performance (sensitivity
92 %, specificity 91 %, diagnostic accuracy 91 %), consistent
with the results by Ferreira et al. [6••, 37]. The specificity of
T1 mapping was significantly higher with native T1 mapping
than that of the combined Lake Louise criteria (sensitivity,
92 %; specificity, 80 %; diagnostic accuracy, 85 %).
ECV quantification has utility in acute to subacute, severe
myocarditis, as shown by Radunski et al. [39], who assessed
the diagnostic performance of T2, T1, and extracellular vol-
ume (ECV) quantification as novel quantitative tissue markers
compared to the Lake Louise criteria. ECV quantificationwith
LGE imaging significantly improved the diagnostic accu-
racy of CMR compared with the Lake Louise criteria, in
patients being evaluated 1–7 weeks after the index
presentation.
T2 Mapping
T2mapping techniques have been shown to allow detection of
myocardial edema beyond standard techniques such as wall
motion abnormalities, T2-weighted, or LGE in a variety of
cardiac pathologies including myocarditis. As shown by
Thavendiranathan et al. [31], T2 mapping has a sensitivity
and specificity of 94 and 97 %, respectively, in detecting
acute inflammatory diseases such as myocarditis and
Takotsubo cardiomyopathy. T2 mapping had also shown
some utility in detecting severe myocarditis up to 7 weeks
after presentation [39].
Overall, while quantitative mapping techniques hold prom-
ise to diagnose myocarditis, establishing which method has
the best diagnostic accuracy is still challenging and requires
further evidence, such as larger studies and multicenter trials.
Sarcoid Myocarditis
Sarcoidosis is a systemic granulomatous inflammatory disease
with unknown etiology that can affect the heart additionally,
or isolated. In case of cardiac involvement, typical manifesta-
tions include arrhythmias, heart failure and/or sudden cardiac
death, which is a frequent cause of death in these patients.
Prevalence of cardiac involvement ranges from 20 to 30 %
[40], depending on the patient population. As described
above, the gold standard endomyocardial biopsy has a low
sensitivity, underlining the need of alternative (non-invasive)
tools for diagnosis and management. In line with the results of
Patel et al. [41], Greulich et al. could clearly demonstrate in a
cohort of 155 patients with suspected cardiac sarcoidosis that
the presence of LGE is correlated with major adverse advents
such as ventricular tachycardia and sudden cardiac death [8•].
Thus, CMR screening for cardiac involvement in patients with
sarcoidosis is now available in the clinical routine. Figure 2
illustrates a typical patient example, in which CMR revealed
cardiac involvement of sarcoid disease.
PET/MRI is a promising approach in patients with known
or suspected cardiac sarcoidosis to detect inflammation with
high sensitivity (active cardiac sarcoidosis), as well as fibrosis
by LGE (chronic cardiac sarcoidosis), which may have impli-
cations for diagnosis and clinical follow-up [42, 43]. First
results are convincing (see Fig. 3), but prospective studies
are needed. In addition, PET imaging is expensive and not
widely available, yet. Furthermore, preparation for PET (12–
18-h fasting to suppress physiologic glucose metabolism by
the heart) and radiation exposure have to be considered in
these (often young) patients. On the other hand, due to the
wide implication of possible cardiac involvement, detailed
diagnostic testing may be warranted.
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Fig. 2 A 61-year-old female presenting with chest pain and elevated
cardiac enzymes. Coronary artery disease (CAD) was ruled out by
coronary angiography. a Cine images showed a slightly diminished left
ventricular ejection fraction (LVEF=53 %). b LGE images revealed an
almost transmural LGE inferoseptal from midventricular to the apex,
from epicardial origin. This pattern could indicate cardiac manifestation
of a systemic disease such as sarcoid. c T2-weighted images demonstrate
hyperintense regions (edema) in the inferoseptal wall (white arrows),
corresponding to LGE. Biopsies were taken, which confirmed the
diagnosis of sarcoidosis, and steroid therapy was initiated
Fig. 3 A 72-year-old woman was referred with increasing shortness of
breath and intermittent chest pain. Echocardiography revealed a
diminished left ventricular ejection fraction (35 %); significant CAD
could be ruled out by coronary angiography. Biopsy of an enlarged
scalene lymph node showed non-caseating granulomas, so cardiac
sarcoid was considered, and a hybrid PET/MRI was scheduled. In the
upper row T2-weighted images are displayed in cine short axis views.
Middle row shows the concomitant LGE images; the presence of LGE is
indicated by the white arrows. In the bottom row, there are fused images
(MRI and PET): note that PET images show an increased uptake in the
border zones of the LGE, suggesting that the process of inflammation
affects more regions than displayed solely by LGE. Far right, CMR
images showing splenic nodules with enhancement on both LGE
sequences and by PET. Reprinted with permission from LWW [42]
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Collagenosis: Systemic Lupus Erythematosus (SLE)
and Systemic Sclerosis (SSc)
The group of collagenosis consists of a heterogenous group of
systemic diseases affecting connective tissue and is character-
ized by necrosis or vasculitis.
Systemic Lupus Erythematosus
This disease affects predominantly females, with cardiac in-
volvement reported in 60–70 % of the patients. These patients
are exposed to an increased risk of coronary atherosclerosis,
which may result in myocardial infarction. Beside of athero-
sclerosis, myocarditis and pericardial effusion could be ob-
served, justifying the use of non-invasive imaging techniques.
The prevalence of LGE in these patients ranges from low to
high in the literature. This might be due to the fact that there is
a wide spectrum of disease activity in these patients. Never-
theless, a study from Mavrogeni et al. [44], which compared
50 patients with suspected infective myocarditis and 25 active
SLE patients to 20 controls revealed that LGE was positive
only in the minority of SLE-active patients, underlining the
need of additional CMR techniques, which can detect inflam-
matory processes.
T1 Mapping and ECV
Native T1 mapping and ECV quantification were able to de-
tect subclinical myocardial involvement in patients with SLE
who were asymptomatic and had normal LV indices [45•].
Compared to normal controls, both native myocardial T1
and extracellular volume fraction (26±5 % vs. 30±6 %) were
significantly increased in patients with SLE, both of which
also correlated with reduced longitudinal strain. Native myo-
cardial T1 values showed the greatest concordance with the
presence of clinical diagnosis of SLE compared to other CMR
markers such as myocardial function, perfusion, and LGE.
Thus, T1 mapping is able to demonstrate subclinical myocar-
dial involvement in systemic diseases otherwise not apparent
on conventional cardiac diagnostic tests.
Systemic Sclerosis
In contrast to SLE, the role of SSc in the pathogenesis of
coronary atherosclerosis is not as well defined: data range
from elevated risk to risk equal to the general population.
There is consensus about potential cardiac involvement,
which can manifest as myocardial damage, disturbances of
the conduction system, pericardial disease, or alterations of
the valves. Aside from that, secondary cardiac complications
may occur due to extracardiac manifestations of SSc: e.g.,
secondary pulmonary hypertension due to sclerotic pulmo-
nary alterations.
A recent study [46] revealed that myocarditis is a
common finding in SSc patients with recent-onset cardi-
ac involvement, presenting with new onset of clinical
symptoms (heart failure, chest pain, palpitations) and el-
evated cardiac enzymes: six out of seven patients showed
LGE; all had evidence of acute or chronic myocarditis by
histology. Only in two out of these six LGE positive
patients, T2 hyperintensity (edema) was present. Despite
the initiation of immunosuppressive treatment, two out of
seven patients suffered SCD. This study underscores,
that, if cardiac involvement is present, LGE may be a
good prognosticator, and these patients may require a
closer observation or maybe even a more aggressive
treatment to decrease the likelihood of adverse cardiovas-
cular events, although larger studies are needed. The
combination of repeated ischemia/vasoconstriction and
inflammation may result in diffuse interstitial fibrosis,
which was reported in endomyocardial biopsies of SSc
patients [47•].
T1 Mapping and ECV
Three groups of investigators have been able to detect
early subclinical myocardial involvement in systemic
sclerosis using T1 mapping and ECV quantification
when there is no apparent cardiac disease. Ntusi et al.
[48] found that in patients with SSc without overt car-
diovascular disease, native T1 values were significantly
elevated, detecting large areas of myocardial abnormality
(median 52 vs. 3 % in controls) and expansion of ECV
(35.4±4.8 vs. 27.6±2.5 %), likely resulting from a com-
bination of low-grade inflammation and diffuse myocar-
dial fibrosis (see Fig. 4). Native T1 and ECV were cor-
related with disease activity and severity, and ECV in-
versely correlated with subclinical myocardial dysfunc-
tion as reflected in impairment in the peak systolic cir-
cumferential strain and peak diastolic strain rate despite
normal biventricular size and systolic function. Thuny
et al. [49] reported similar findings in patients with
SSc, normal LV systolic function, and no LGE, who
had significantly increased ECV (median 30.0 vs.
26.8 % in controls), which correlated with left atrial vol-
ume and diastolic dysfunction. Barison et al. [50] also
demonstrated ECV expansion in asymptomatic SSc pa-
tients with normal LV systolic function and without
LGE, both in the myocardium (30±4 % vs. 28±4 % in
controls) and in skeletal muscle (23±6 % vs. 18±4 %).
T1 mapping and ECV quantification can detect subclin-
ical myocardial disease in this condition and may identi-
fy patients with early myocardial involvement, with po-
tential to treat early before permanent irreversible injury
occurs.
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Churg-Strauss Syndrome
The vasculitides encompass a wide spectrum of diseases
with different entities. Aside from large-vessel vasculitis
(e.g., Takayasu, Kawasaki), vasculitis of the small vessels
(EGPA=eosinophilic granulomatosis with polyangiitis, al-
so known as Churg-Strauss syndrome) has gained atten-
tion, showing some impressive cardiac manifestation
leading to impaired left ventricular function. Interestingly,
LGE images show a subendocardial and also intramural
pattern, sometimes resembling ischemic heart disease,
but typically not related to a coronary territory,
representing destructed coronary capillaries due to the in-
flammation process. More recent advances in characteriz-
ing inflammation by mapping sequences seem promising,
but there is no published data yet.
Rheumatoid Arthritis (RA)
Patients with rheumatoid arthritis (RA) suffer accelerated ath-
erosclerosis. The prevalence of myocardial tissue involvement
is very variable in the literature, due to different inclusion
criteria and patient population.
Ntusi et al. [51] compared 39 RA patients (28 fe-
male, mean age 50±12 years, diagnosed with RA for
a median of 7 years, mean DAS28-CRP score 3.3±
1.3) to 39 matched controls, all without previously
known cardiovascular disease using CMR at 1.5 T, in-
cluding cine, T2-weighted, native T1 mapping, ECV
quantification, and LGE imaging. RA patients had larger
areas of focal myocardial edema on T2-weighted imag-
ing (median 10 vs. 0 % LV involvement). Forty-six
percent had LGE, of which 28 % showed a midwall
pattern and 13 % patchy enhancement; two patients
(5 %) revealed previously unknown myocardial infarc-
tion, subsequently confirmed to have a significant CAD
on angiography. Overall, however, the LGE burden was
small (3.7±0.4 % of total LV mass).
T1 Mapping and ECV
Further, the utility of T1 mapping and ECV has been
shown in patients with RA but no prior history of car-
diovascular disease and normal LV indices [51]. Com-
pared to normal controls, native T1 and ECV (30.3±
3.4 % vs. 27.9±2.0 %) were significantly elevated in
Fig. 4 Cardiac magnetic
resonance images from a 48-year-
old patient with systemic sclerosis
(SSc), with a normal left
ventricular (LV) ejection fraction
of 63 %. a LGE imaging with no
focal areas of enhancement. b T2
map. c Native T1 map (acquired
using ShMOLLI at 1.5 T) showed
significantly elevated average LV
myocardial T1 values of 1009±
47 ms (normal 962±25 ms). d
Post-contrast T1 map acquired at
15 min after gadolinium
administration. Average post-
contrast T1 values were 479±
18 ms. Extracellular volume
(ECV) quantification using pre-
and post-contrast T1 mapping and
adjusting for the hematocrit
demonstrated a significant
expansion of interstitial space at
40 % (normal 27±3 %). Images
courtesy Dr. Ntobeko Ntusi,
University of Oxford
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these patients, regardless of the presence of LGE, and
both correlated with impaired peak systolic and diastolic
strain and RA disease activity. In RA patients with ap-
parently normal hearts, subclinical myocardial involve-
ment can be detected using conventional and mapping
CMR techniques, which show focal myocardial fibrosis,
inflammation, and expansion of extracellular space, like-
ly reflecting a degree of diffuse myocardial fibrosis in
this systemic disease. T1 mapping and ECV quantifica-
tion may provide incremental value as novel biomarkers
for early disease detection, monitoring, and determining
response to therapy in systemic inflammatory diseases.
Conclusion
In summary, CMR techniques are able to provide detailed
information about myocardial inflammation. LGE is the most
validated tool for diagnosis and prognosis, but has limitations
in detecting acute inflammatory processes without scar or fi-
brosis. EGE and T2-weighted imaging may be useful in in-
creasing the diagnostic accuracy of acute inflammatory myo-
cardial processes in selected cases but can be challenging to
apply in the practical clinical setting due to recognized tech-
nical and methodological limitations. Novel quantitative map-
ping techniques seem very promising, as they can detect ede-
ma as well as fibrosis while circumventing some of the chal-
lenges of conventional CMR techniques, allowing a more
holistic approach to the different stages of inflammation. Pro-
spective multicenter studies are warranted to clarify the future
role of their clinical utility.
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